PsychoGenics expands its Drug Discovery Service Capabilities
Wednesday, January 20, 2016
PsychoGenics Inc. announced that it has acquired equipment and hired experienced scientists from Lundbeck Research USA and is now in a position to offer expanded services in the areas of bioanalysis, in vivo microdialysis, EEG and quantitative histology. In August 2015, Lundbeck announced that it will close its research operation in Paramus NJ. Following this announcement PsychoGenics and Lundbeck began discussions to preserve jobs, which has now been accomplished.
Commenting on the expansion, Emer Leahy, PhD, President and CEO of PsychoGenics stated: “We are delighted to have the opportunity to hire talented scientists from Lundbeck. In total 10 scientists, each with more than ten years of experience in their respective fields, will be dedicated to microdialysis, bioanalysis, EEG and quantitative histology. These expanded areas of research complement PsychoGenics already well established capabilities and when applied to our animal models will further enhance our understanding of CNS disease.”
psychogenics.com
